Stella Diagnostics (Stella Diagnostics) Receivables Turnover : 0.00 (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Stella Diagnostics Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Stella Diagnostics's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Stella Diagnostics's average Accounts Receivable for the three months ended in Sep. 2023 was $0.00 Mil.

Stella Diagnostics Receivables Turnover Historical Data

The historical data trend for Stella Diagnostics's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stella Diagnostics Receivables Turnover Chart

Stella Diagnostics Annual Data

Trend

Receivables Turnover

Stella Diagnostics Quarterly Data
	Sep22	Sep23
Receivables Turnover	-	-

Competitive Comparison of Stella Diagnostics's Receivables Turnover

For the Diagnostics & Research subindustry, Stella Diagnostics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stella Diagnostics's Receivables Turnover Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Stella Diagnostics's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Stella Diagnostics's Receivables Turnover falls into.

Stella Diagnostics Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Stella Diagnostics's Receivables Turnover for the fiscal year that ended in . 20 is calculated as

	Receivables Turnover (A: . 20 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: . 20 )	/ (	(Accounts Receivable (A: . 20 )	+	Accounts Receivable (A: . 20 ))	/	count )
=		/ (	(	+	)	/	1 )
=		/	0
=	N/A

Stella Diagnostics's Receivables Turnover for the quarter that ended in Sep. 2023 is calculated as

	Receivables Turnover (Q: Sep. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Sep. 2023 )	/ (	(Accounts Receivable (Q: Sep. 2022 )	+	Accounts Receivable (Q: Sep. 2023 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Stella Diagnostics (OTCPK:SLDX) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Stella Diagnostics Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Stella Diagnostics's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Stella Diagnostics (Stella Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Stella Diagnostics Inc (OTCPK:SLDX) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 West Broadway, Suite 300, Salt Lake City, UT, USA, 84104

Website

https://www.stelladx.com

Stella Diagnostics Inc is a molecular diagnostics-based organization focused on improving patient management strategies for people living with severe esophageal disease. It is developing first-line diagnostic tools that provide superior molecular information for providers as compared to the current standard screening protocols.